<DOC>
	<DOCNO>NCT01022515</DOCNO>
	<brief_summary>Pheochromocytoma paraganglioma tumor generate hypertension symptom . Different biological test currently available diagnose tumor . However , lack specificity since distinguish case hypertension without pheochromocytoma paraganglioma . To improve diagnostic specificity tumor , investigator test new marker call EM66 .</brief_summary>
	<brief_title>Specificity Elevated Plasma EM66 Levels Pheochromocytoma</brief_title>
	<detailed_description>Neuroendocrine tumor ( NT ) correspond neoplasm develop endocrine neuroendocrine cell scatter throughout body . They characterize occurrence , cytoplasm , dense-core secretory vesicle contain hormone , neuropeptides acidic protein granins . The diversity NT ( hypophysis , pancreas , adrenal , gastrointestinal tract ) make difficult identification evaluation different type tumor diagnostic prognostic tool currently available . We thus establish research program aim identify new biological marker detection , prognosis follow-up NT seek tumor plasma sample patient , granin-derived peptide . Our program initiate one type NT : pheochromocytoma . These neoplasms correspond tumoral chromaffin cell mainly originate adrenal medulla . It consider 10 % pheochromocytoma patient develop metastasis , currently , except presence metastasis , mean predict malignancy tumor . We setup radioimmunoassay EM66 ( secretogranin II-derived peptide ) allow u demonstrate ( ) plasma concentration peptide significantly elevate pheochromocytoma patient , ( ii ) combine biological test EM66 measurement increase diagnostic sensitivity neoplasm , ( iii ) surgical removal tumor , plasma EM66 concentration rapidly return basal level , ( iv ) intra-tumoral EM66 concentration higher benign malignant pheochromocytoma ( Yon et al. , 2003 , Guillemot et al. , 2006 ) . These result reveal EM66 constitutes novel tool diagnosis , prognosis follow-up pheochromocytoma . In frame clinical use EM66 measurement test , necessary evaluate specificity marker . For instance , renal deficiency , hypergastrinemia , reduction renal clearance , type A gastritis , Crohns disease , proton-pump inhibitory treatment , lead increase plasma chromogranin A ( CgA ) concentration ( false-positive case ) . In addition , hypertension account one symptom pheochromocytoma patient , essential hypertensive patient , CgA level higher normotensive individual . The main objective clinical transfer research project consist study specificity measurement EM66 diagnostic prognostic marker pheochromocytoma . This multicentric study allow u compare plasma EM66 level pheochromocytoma patient cohort essential hypertensive patient . At time , long-range prospect , due lack malignancy marker tumor , investigate plasma tumor EM66 level correlate differentiation status pheochromocytoma , expression level set gene identify transcriptomic approach develop laboratory , associate malignant status tumor . The stake transfer research , involve laboratory Center Clinical Investigations ( CIC ) Rouen Lille , provide easy simple novel tool practitioner anatomo-pathologists screening , evaluation follow-up patient neuroendocrine tumor .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>Paraganglioma</mesh_term>
	<mesh_term>Carotid Body Tumor</mesh_term>
	<criteria>Patients pheochromocytoma/paraganglioma Inclusion criterion : men &amp; woman , age &gt; 18 year old Newly diagnose patient : suspicion pheochromocytoma paraganglioma elevation urinary metanephrines and/or normetanephrines along evidence tumor surgical removal consider ( histological finding follow surgery gold standard final diagnosis inclusion study ) During followup patient know genetic predisposition pheochromocytoma/paraganglioma : suspicion pheochromocytoma paraganglioma without elevation urinary metanephrines and/or normetanephrines along evidence tumor surgical removal consider ( histological finding follow surgery gold standard final diagnosis inclusion study ) , Patients know pheochromocytoma/paraganglioma , whether malignant , whether metanephrine secretion , With tumor site inclusion study Patients inform willing participate study Patients medical insurance ( French social security ) Non inclusion criterion Patients newly diagnose , recently operate histological finding disprove pheochromocytoma paraganglioma . patient imprison legal protection . Patients essential hypertension Inclusion criterion men &amp; woman , age &gt; 18 year old pair patient pheochromocytoma/paraganglioma : gender , age ( Â± 5 year ) centre patient hypertension . No aetiology find initial check . Normal 24 hour urinary excretion metanephrines &amp; normetanephrines For woman childbearing potential : effective contraceptive method negative urinary pregnancy test Patients inform willing participate study Patients medical insurance ( French social security ) Non inclusion criterion Treatment protonpump inhibitor 8 day inclusion study Treatment betablockers , antidepressant , Benzodiazepins , dopa , alphamethyl dopa , treatment interrupt study ( i.e . approximately 10 day ) patient imprison legal protection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>pheochromocytoma</keyword>
	<keyword>paraganglioma</keyword>
	<keyword>hypertension</keyword>
</DOC>